CARTITUDE-1: Two-year post last patient in (LPI) results from the phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in patients with relapsed/refractory multiple myeloma (RRMM) Meeting Abstract

  

Authors:	Usmani, S. Z.; Martin, T.; Berdeja, J. G.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Deol, A.; Htut, M.; Lesokhin, A.; Munshi, N. C.; O'Donnell, E.; Jackson, C. C.; Yeh, T. M.; Banerjee, A.; Zudaire, E.; Madduri, D.; Zhou, C. W.; Pacaud, L.; Lin, Y.; Jagannath, S.
Abstract Title:	CARTITUDE-1: Two-year post last patient in (LPI) results from the phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) cell therapy, in patients with relapsed/refractory multiple myeloma (RRMM)
Meeting Title:	10th Annual Meeting of the Society of Hematologic Oncology (SOHO)
Keywords:	multiple myeloma; phase i/ii; mm; car-t cell therapy; cilta-cel
Journal Title:	Clinical Lymphoma, Myeloma and Leukemia
Volume:	22
Issue:	Suppl. 2
Meeting Dates:	2022 Sep 28-Oct 1
Meeting Location:	Houston, TX
ISSN:	2152-2650
Publisher:	Elsevier Inc.
Date Published:	2022-10-01
Start Page:	S410
End Page:	S411
Language:	English
ACCESSION:	WOS:000897948100478
PROVIDER:	wos
DOI:	10.1016/s2152-2650(22)01599-3
Notes:	Meeting Abstract: MM-181 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/205276